ImaRx Therapeutics, Inc. company was founded in 1999. ImaRx Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on the development of therapies for stroke and other vascular disorders, using its microbubble technology. Its lead program, SonoLysis, involves the administration of its MRX-801 microspheres and ultrasound to break up blood clots and restore blood flow to oxygen deprived tissues. The MRX-801 microspheres are a proprietary formulation of a lipid shell encapsulating an inert biocompatible gas. Discontinued operations In September 2008, the company divested its urokinase business to Microbix.

Incyte hopes its success with inhibitors is uninhibited. The biotechnology company is focused on discovering and developing drugs that inhibit specific enzymes associated with cancer, diabetes, HIV, and inflammatory diseases. The company's lede program is its JAK kinase inhibitor program, which covers treatments for inflammatory diseases and cancers, including rheumatoid arthritis, myelofibrosis, psoriasis, multiple myeloma, and prostate cancer. Incyte has several other products in clinical trial stages, including a CCR5 antagonist designed to prevent the entry of HIV into target cells.

American Oriental Bioengineering, Inc. (AOB) is an integrated, pharmaceutical company engaged in the development, manufacture and commercialization of a range of pharmaceutical and healthcare products. The Company’s business comprises prescription pharmaceutical products, over-the-counter (OTC) pharmaceutical products and nutraceutical products. Its pharmaceutical products have been approved by the Chinese State Food and Drug Administration (SFDA). The Company sells its products primarily to hospitals, clinics, pharmacies and retail outlets at over 100,000 locations in all provinces, including rural areas and cities in China. During the year ended December 31, 2008, AOB marketed over 60 pharmaceutical products in China. On October 18, 2008, the Company acquired Nuo Hua Investment Company Limited. On October 20, 2008, the Company acquired GuangXi HuiKe Pharmaceutical Research and Development Co., Ltd.

ProStrakan Group plc company specializes in those areas, but also focuses on therapies for women's health and issues relating to the ageing male. ProStrakan's marketed products include brain tumor treatment Bélustine and bone therapy Adcal. Products in development include therapies to treat alopecia and hypogonadism. ProStrakan markets its products to more than 10 countries in the EU, and has applied for FDA approval of pain medication Abstral in the US. ProStrakan company was founded as Strakan in 1995 by Chairman Harry Stratford and changed its name to ProStrakan when it merged with ProSkelia. Warbug Pincus and Aventis Pharma each hold majority shares in the company.

Dyax Corp. was founded in 1989 and is headquartered in Cambridge, Massachusetts. Dyax Corp. (Dyax) is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel biotherapeutics for unmet medical needs, with an emphasis on inflammatory and oncology indications. The Company uses the drug discovery technology, known as phage display, to identify antibody, small protein and peptide compounds for clinical development. The Company’s product DX-88 (ecallantide), is in late stage clinical trial development in two separate indications. In addition to DX-88, the phage display technology has allowed Dyax to develop a substantial pipeline of drug candidates. In June 2008, the Company completed a second phase three study, known as EDEMA4.

EMD Serono develops a potpourri of prescription pharmaceuticals used for the treatment of neurological, metabolic, and fertility disorders and diseases such as multiple sclerosis (MS), lupus, and HIV. The Massachusetts-based company conducts research and development programs in the US and markets products that include Gonal-f, Luveris, Ovidrel, Rebif, and Zorbtive in the US and Canada. The company has manufacturing and marketing agreements with other pharmaceutical firms, including Pfizer (MS) and CuraScript (fertility). EMD Serono is the North American operating subsidiary of Merck Serono S.A..

Quest PharmaTech aims to shed some light on dermatology and cancer treatments. Working with Hypocrellin, a photosensitive compound isolated from pigments found in fungi on bamboo, the company has developed its SonoLight Technology. The compound is relatively harmless until activated by light or ultrasound, whereupon it begins to destroy tissue. The company's pipeline of drug candidates include treatments to facilitate laser hair removal, address acne, and improve prostate cancer therapies. The company has sold off several earlier products to focus on its current pipeline and continues to consider strategic alternatives to facilitate its growth.

ARCA biopharma, Inc. (ARCA), formerly Nuvelo, Inc. is a biopharmaceutical company focused on developing genetically-targeted therapies for heart failure and other cardiovascular diseases. ARCA’s lead product candidate Gencaro (bucindolol hydrochloride), a beta-blocker and mild vasodilator is under review by the United States Food and Drug Administration (FDA), for chronic heart failure (HF). Gencaro is an oral tablet formulation, dosed twice daily. On January 27, 2009, Nuvelo, Inc. (Nuvelo) completed the merger with ARCA biopharma, Inc. (ABI). Pursuant to the Merger, Dawn Acquisition Sub, Inc. merged with and into ABI, with ABI continuing after the merger as the surviving company and a wholly owned subsidiary of Nuvelo. Pursuant to the Merger, ABI changed its name to ARCA biopharma Colorado, Inc. and Nuvelo changed its name to ARCA biopharma, Inc.

Norgine Limited was founded in 1906 and is based in Harefield, the United Kingdom with regional offices in Tunisia and Saudi Arabia. It has manufacturing sites in Dreux, France; and Hengoed, the United Kingdom. The company has subsidiaries in the United Kingdom, France, Germany, Belgium, the Netherlands, Denmark, Switzerland, Austria, Italy, and Spain, as well as in Australia, and South Africa. Norgine Limited is a subsidiary of Norgine Europe B.V. Norgine Limited, a specialty pharmaceutical company, develops, manufactures, and markets products in the areas of gastroenterology, hepatology, and pain management in Europe. It offers products for the treatment of chronic constipation and faecal impaction, bowel preparation prior to colonoscopy, ulcerative colitis, Crohn's disease, duodenal and benign gastric ulcers, traveler’s diarrhoea, and pain, as well as provides antitussive medications and products for the relief of smooth muscle spasm. The company also provides assistance in the development and launch of pharmaceutical products for companies.

Allermed Laboratories, Inc. company was founded in 1971. Allermed Laboratories knows that in the case of allergies, a little bit of what caused the problem can be the solution. The company manufactures allergenic extracts, such as plant pollens, insects, fish and shellfish, and various foods, used to both diagnose and treat allergic conditions. The company is also developing additional skin tests for allergies, as well new tests to detect Leishmania parasite infections and exposure to the fungus Coccidioides immitis. Other products include empty test vials, vial trays, diluents, and extract mixing syringes. Outside of allergists' offices, the company provides environmental testing kits to detect mold contamination of buildings.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.